Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
$5.95
+3.8%
$6.90
$3.80
$10.90
$25.82M-0.916,244 shs1,664 shs
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
$1.71
+0.6%
$1.81
$1.32
$2.72
$249.73M1.71192,014 shs16,498 shs
Otonomy, Inc. stock logo
OTIC
Otonomy
$0.01
$0.06
$0.01
$2.54
$582K1.54937,525 shsN/A
Savara Inc. stock logo
SVRA
Savara
$2.14
+1.7%
$2.60
$1.89
$5.11
$369.01M0.311.27 million shs1.11 million shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
+5.85%+10.47%-17.72%+39.98%-38.75%
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
+0.59%+4.91%-7.82%+14.00%-13.64%
Otonomy, Inc. stock logo
OTIC
Otonomy
0.00%0.00%0.00%0.00%0.00%
Savara Inc. stock logo
SVRA
Savara
+1.67%-3.39%-11.04%-25.09%-50.69%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
0.885 of 5 stars
0.05.00.00.00.01.70.6
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
0.9286 of 5 stars
3.51.00.00.00.00.00.0
Otonomy, Inc. stock logo
OTIC
Otonomy
N/AN/AN/AN/AN/AN/AN/AN/A
Savara Inc. stock logo
SVRA
Savara
1.8395 of 5 stars
3.31.00.00.00.03.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
0.00
N/AN/AN/A
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
3.00
Buy$7.00309.36% Upside
Otonomy, Inc. stock logo
OTIC
Otonomy
0.00
N/AN/AN/A
Savara Inc. stock logo
SVRA
Savara
2.60
Moderate Buy$5.60162.30% Upside

Current Analyst Ratings Breakdown

Latest CCM, SVRA, OTIC, and IMMP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/29/2025
Savara Inc. stock logo
SVRA
Savara
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$6.00 ➝ $2.00
5/28/2025
Savara Inc. stock logo
SVRA
Savara
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetIn-Line ➝ In-Line$3.00 ➝ $2.00
5/28/2025
Savara Inc. stock logo
SVRA
Savara
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00 ➝ $8.00
5/28/2025
Savara Inc. stock logo
SVRA
Savara
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$8.00 ➝ $7.00
(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
$52.60M0.49N/AN/A$51.05 per share0.12
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
$5.14M48.59N/AN/A$1.05 per share1.63
Otonomy, Inc. stock logo
OTIC
Otonomy
$130K4.48N/AN/A$0.97 per share0.01
Savara Inc. stock logo
SVRA
Savara
N/AN/AN/AN/A$1.00 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
-$42.23MN/A0.00N/AN/AN/AN/AN/A
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
-$28.01MN/A0.00N/AN/AN/AN/AN/A7/29/2025 (Estimated)
Otonomy, Inc. stock logo
OTIC
Otonomy
-$51.18M-$0.77N/AN/AN/A-137.86%-68.50%N/A
Savara Inc. stock logo
SVRA
Savara
-$95.88M-$0.48N/AN/AN/AN/A-65.88%-52.35%8/11/2025 (Estimated)

Latest CCM, SVRA, OTIC, and IMMP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Savara Inc. stock logo
SVRA
Savara
-$0.12-$0.12N/A-$0.12N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
N/AN/AN/AN/AN/A
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
N/AN/AN/AN/AN/A
Otonomy, Inc. stock logo
OTIC
Otonomy
N/AN/AN/AN/AN/A
Savara Inc. stock logo
SVRA
Savara
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
1.67
0.46
0.45
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
N/A
18.86
N/A
Otonomy, Inc. stock logo
OTIC
Otonomy
N/A
1.74
1.74
Savara Inc. stock logo
SVRA
Savara
0.20
14.91
14.91

Institutional Ownership

CompanyInstitutional Ownership
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
N/A
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
2.32%
Otonomy, Inc. stock logo
OTIC
Otonomy
41.23%
Savara Inc. stock logo
SVRA
Savara
87.93%

Insider Ownership

CompanyInsider Ownership
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
46.50%
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
3.07%
Otonomy, Inc. stock logo
OTIC
Otonomy
1.09%
Savara Inc. stock logo
SVRA
Savara
5.33%
CompanyEmployeesShares OutstandingFree FloatOptionable
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
9704.34 million2.32 millionNot Optionable
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
2,021146.04 million141.56 millionOptionable
Otonomy, Inc. stock logo
OTIC
Otonomy
5168.53 million67.78 millionOptionable
Savara Inc. stock logo
SVRA
Savara
N/A172.84 million163.63 millionOptionable

Recent News About These Companies

Savara Independent Director Acquires 177% More Stock

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Concord Medical Services stock logo

Concord Medical Services NYSE:CCM

$5.95 +0.22 (+3.82%)
As of 07/3/2025 01:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Concord Medical Services Holdings Limited, through its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. It operates in two segments, Network and Hospital. The company's services include linear accelerators and external beam radiotherapy, proton therapy system, gamma knife radiosurgery, and diagnostic imaging services. Its other treatments and diagnostic services comprise positron emission tomography-computed tomography and magnetic resonance imaging scanners. In addition, the company provides clinical support services, such as developing treatment protocols for doctors, and organizing joint diagnosis between doctors in its network and clinical research, as well as helps to recruit and determine the compensation of doctors and other medical personnel. Further, it offers radiotherapy and diagnostic equipment leasing, management services, and premium cancer and proton treatment services to hospitals, as well as teleconsultation and medical information technology services; and sells medical equipment. Additionally, the company operates specialty cancer hospitals, which offers radiation, imaging, test laboratory, inpatient, and nursing services. Concord Medical Services Holdings Limited was founded in 1997 and is headquartered in Beijing, the People's Republic of China.

Prima BioMed stock logo

Prima BioMed NASDAQ:IMMP

$1.71 +0.01 (+0.59%)
As of 07/3/2025 03:31 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

Otonomy stock logo

Otonomy NASDAQ:OTIC

Otonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA.

Savara stock logo

Savara NASDAQ:SVRA

$2.13 +0.04 (+1.67%)
Closing price 07/3/2025 03:58 PM Eastern
Extended Trading
$2.19 +0.06 (+2.81%)
As of 07/3/2025 04:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.